[Effect of local immunotherapy of interleukin 2(IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas].
OBJECTIVE
To evaluate the effect of locoregional immunotherapy of interleukin 2 (IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas.


METHODS
Thirty-four patients with stage T3 or T4 oral squamous cell carcinoma were randomly divided into two groups, and treated with two therapies. 23 cases of them received immunochemotherapy and 11 cases received PVP chemotherapy. Changes of T lymphocyte subsets and B cells at tumor site in the two groups were compared before and after therapy.


RESULTS
The relative numbers of CD4+, CD8+, CD20+ before and after treatment in immunochemotherapy were respectively 36.96, 35.65, 28.65 and 56.61, 38.52, 38.70. The numbers of CD4+, CD20+ increased significantly after immunochemotherapy. However, in chemotherapy group, there was no significant difference in numbers of CD4+, CD8+ and CD20+ cells between pre and post treatment.


CONCLUSIONS
Immunochemotherapy for oral squamous cell carcinomas may play an important role in increasing local immunity.
Tang
Enyi
E
Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital, Nanjing University Medical School, Nanjing 210008, China.
Hu
Qingang
Q
Zhou
Bingrong
B
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014750:Vincristine / Q000008:administration & dosage
D007376:Interleukin-2; D001761:Bleomycin; D014750:Vincristine; C021771:zhengguangmycin; D002945:Cisplatin